Trevi Therapeutics 将来の成長

Future 基準チェック /06

Trevi Therapeuticsは、12.1%と96.9%でそれぞれ年率12.1%で利益と収益が成長すると予測される一方、EPSはgrowで18.6%年率。

主要情報

12.1%

収益成長率

18.6%

EPS成長率

Pharmaceuticals 収益成長	23.7%
収益成長率	96.9%
将来の株主資本利益率	n/a
アナリストカバレッジ	Good
最終更新日	08 Nov 2024

今後の成長に関する最新情報

Recent updates

We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth

Sep 27

We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth

May 24

Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans

Jan 27

業績と収益の成長予測

NasdaqGM:TRVI - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	1	-63	-69	-54	9
12/31/2025	N/A	-57	-59	-57	9
12/31/2024	N/A	-50	-51	-44	9
9/30/2024	N/A	-44	-35	-35	N/A
6/30/2024	N/A	-39	-33	-33	N/A
3/31/2024	N/A	-34	-34	-34	N/A
12/31/2023	N/A	-29	-32	-32	N/A
9/30/2023	N/A	-27	-32	-32	N/A
6/30/2023	N/A	-27	-33	-33	N/A
3/31/2023	N/A	-28	-29	-29	N/A
12/31/2022	N/A	-29	-28	-28	N/A
9/30/2022	N/A	-32	-28	-28	N/A
6/30/2022	N/A	-31	-27	-27	N/A
3/31/2022	N/A	-33	-28	-28	N/A
12/31/2021	N/A	-34	-29	-29	N/A
9/30/2021	N/A	-35	-32	-32	N/A
6/30/2021	N/A	-35	-31	-31	N/A
3/31/2021	N/A	-33	-32	-32	N/A
12/31/2020	N/A	-33	-29	-29	N/A
9/30/2020	N/A	-30	-26	-26	N/A
6/30/2020	N/A	-30	-27	-27	N/A
3/31/2020	N/A	-29	-24	-24	N/A
12/31/2019	N/A	-27	-23	-23	N/A
9/30/2019	N/A	-28	-22	-22	N/A
6/30/2019	N/A	-27	-18	-18	N/A
3/31/2019	N/A	-27	-19	-18	N/A
12/31/2018	N/A	-26	-18	-18	N/A
9/30/2018	N/A	-22	-16	-16	N/A
12/31/2017	N/A	-13	N/A	-8	N/A

アナリストによる今後の成長予測

収入対貯蓄率: TRVI今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: TRVI今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: TRVI今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: TRVI来年は収益がないと予測されています。

高い収益成長: TRVI来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: TRVIの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Trevi Therapeutics 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target decreased to US$8.75

Price target increased to US$10.00

Price target decreased to US$8.67

Price target decreased to US$10.00

Forecast to breakeven in 2025

Price target raised to US$11.67

Recent updates

Trevi Therapeutics, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Trevi Therapeutics, Inc. Completes Enrollment in the Phase 2A RIVER Trial of Haduvio

Trevi Therapeutics, Inc. Announces Updates on Its Clinical Development Programs

Trevi Therapeutics Appoints James V. Cassella as Chief Development Officer

We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth

Trevi Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth

Trevi Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Trevi Therapeutics, Inc. to Report Q4, 2023 Results on Mar 20, 2024

Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans

New minor risk - Share price stability

Trevi Therapeutics, Inc. Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio™ for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)

New minor risk - Market cap size

Trevi Therapeutics, Inc. Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio™? for Refractory Chronic Cough

Trevi Therapeutics, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Trevi Therapeutics, Inc. Announces Results from Phase 2b/3 Prism Open-Label Extension Study of Haduvio in Prurigo Nodularis

Trevi Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Insufficient new directors

Trevi Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023

Price target decreased to US$8.75

Trevi Therapeutics, Inc. Appoints David Clark as Chief Medical Officer

Trevi Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $54.990753 million.

Trevi Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $50 million.

Trevi Therapeutics Announces Positive Data from Full Set of Subjects in Phase 2 CANAL Trial of Haduvio™ in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis

Trevi adds 19% on full data set from mid-stage cough study

Trevi Therapeutics: Moving Forward

Price target increased to US$10.00

Trevi Therapeutics Inc. Reports Positive Results from the Ph2b/3 PRISM Trial of Haduvi in Treatment of Prurigo Nodularis

Trevi Therapeutics, Inc.(NasdaqGM:TRVI) dropped from Russell Microcap Value Index

Trevi Therapeutics, Inc. to Report Q1, 2022 Results on May 12, 2022

Trevi Therapeutics, Inc., Annual General Meeting, Jun 23, 2022

Price target decreased to US$8.67

Trevi Therapeutics, Inc. announced that it has received $54.999998 million in funding from Fairmount Funds Management LLC, Frazier Management, L.L.C., New Enterprise Associates, Inc., VR Adviser, LLC

Trevi Therapeutics, Inc. announced that it expects to receive $54.999998 million in funding from Fairmount Funds Management LLC, Frazier Management, L.L.C., New Enterprise Associates, Inc., VR Adviser, LLC

Is Trevi Therapeutics (NASDAQ:TRVI) Using Too Much Debt?

Trevi Therapeutics, Inc. Reports Statistically Significant Result on Interim Analysis from the Ph2 Canal Trial of Nalbuphine Er in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis

Trevi Therapeutics, Inc. Completes Enrollment for Phase 2b/3 PRISM Study in Chronic Pruritus in PN

Trevi Therapeutics Announces Clinical Trial Updates for Lead Indications

Price target decreased to US$10.00

Forecast to breakeven in 2025

Chief Financial Officer has left the company

Trevi Therapeutics, Inc. to Report Q4, 2020 Results on Mar 25, 2021

New 90-day low: US$2.36

Price target raised to US$11.67

Trevi Therapeutics Appoints William Forbe as Chief Development Officer

Trevi has a new development chief

New 90-day low: US$2.65

New 90-day low: US$2.97

New 90-day low: US$3.10

Trevi Therapeutics, Inc. to Report Q3, 2020 Results on Nov 11, 2020

New 90-day low: US$3.49

New 90-day low - US$3.50

Trevi Therapeutics, Inc. to Report Q2, 2020 Results on Aug 13, 2020

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘